Li, Na Wang, Jianing Zhang, Na Zhuang, Mengwei Zong, Zhaoyun Zou, Jiahuan Li, Guosheng Wang, Xiaoyan Zhou, Huaiyu Zhang, Lining
...
Published in
Cancer immunology, immunotherapy : CII
Clinical benefit from immunotherapy of B7-H1/PD-1 checkpoint blockade indicates that it is important to understand the regulatory mechanism of B7-H1 expression in cancer cells. As an adaptive response to the endogenous antitumor immunity, B7-H1 expression is up-regulated in HCC cells. B7-H1 expression is induced mainly by IFN-γ released from tumor-...
Gasser, Olivier Sharples, Katrina J Barrow, Catherine Williams, Geoffrey M Bauer, Evelyn Wood, Catherine E Mester, Brigitta Dzhelali, Marina Caygill, Graham Jones, Jeremy
...
Published in
Cancer immunology, immunotherapy : CII
Vaccines that elicit targeted tumor antigen-specific T-cell responses have the potential to be used as adjuvant therapy in patients with high risk of relapse. However, the responses induced by vaccines in cancer patients have generally been disappointing. To improve vaccine function, we investigated the possibility of exploiting the immunostimulato...
Obeid, Joseph M Kunk, Paul R Zaydfudim, Victor M Bullock, Timothy N Slingluff, Craig L Jr. Rahma, Osama E
Published in
Cancer immunology, immunotherapy : CII
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and the second most common cause of cancer death worldwide. Current treatment options for patients with intermediate and advanced HCC are limited, and there is an unmet need for novel therapeutic approaches. HCC is an attractive target for immunomodulation therapy, since it ...
Zou, Ming-Xiang Guo, Ke-Miao Lv, Guo-Hua Huang, Wei Li, Jing Wang, Xiao-Bin Jiang, Yi She, Xiao-Ling
Published in
Cancer immunology, immunotherapy : CII
Currently, little is known about the interactions between microRNAs (miRNAs) and the PD-1/PD-L1 signaling pathway in chordoma, and data discussing the role of the immune milieu in chordoma prognosis are limited. We aimed to analyze the relationship between PD-L1, miR-574-3p, microenvironmental tumor-infiltrating lymphocytes (TILs) and clinicopathol...
Moore, Tamson Wagner, Courtney Regan Scurti, Gina M Hutchens, Kelli A Godellas, Constantine Clark, Ann Lau Kolawole, Elizabeth Motunrayo Hellman, Lance M Singh, Nishant K Huyke, Fernando A
...
Published in
Cancer immunology, immunotherapy : CII
Malignant melanoma incidence has been increasing for over 30 years, and despite promising new therapies, metastatic disease remains difficult to treat. We describe preliminary results from a Phase I clinical trial (NCT01586403) of adoptive cell therapy in which three patients received autologous CD4+ and CD8+ T cells transduced with a lentivirus ca...
Liu, Qi Zhu, Hongda Liu, Yun Musetti, Sara Huang, Leaf
Published in
Cancer immunology, immunotherapy : CII
Approximately, 50% of human melanomas are driven by BRAF mutations, which produce tumors that are highly immunosuppressive and often resistant to vaccine therapy. We introduced lipid-coated calcium phosphate nanoparticles (LCP NPs) as a carrier to efficiently deliver a tumor-specific antigen, the BRAFV600E peptide, to drive dendritic cell (DC) matu...
Fisher, Timothy S Hooper, Andrea T Lucas, Justin Clark, Tracey H Rohner, Allison K Peano, Bryan Elliott, Mark W Tsaparikos, Konstantinos Wang, Hui Golas, Jonathan
...
Published in
Cancer immunology, immunotherapy : CII
Strong evidence exists supporting the important role T cells play in the immune response against tumors. Still, the ability to initiate tumor-specific immune responses remains a challenge. Recent clinical trials suggest that bispecific antibody-mediated retargeted T cells are a promising therapeutic approach to eliminate hematopoietic tumors. Howev...
Wei, Yichou Lin, Chao Li, He Xu, Zhiying Wang, Jieti Li, Ruochen Liu, Hao Zhang, Heng He, Hongyong Xu, Jiejie
...
Published in
Cancer immunology, immunotherapy : CII
Intratumoral CXCL13 expression appears as an independent prognostic marker for patients after gastric cancer resection. In addition, CXCL13 expression may serve as a predictive biomarker of response to postoperative adjuvant chemotherapy in these patients.
Liu, Zhenjiang Poiret, Thomas Persson, Oscar Meng, Qingda Rane, Lalit Bartek, Jiri Jr. Karbach, Julia Altmannsberger, Hans-Michael Illies, Christopher Luo, Xiaohua
...
Published in
Cancer immunology, immunotherapy : CII
The prognosis for patients with glioblastoma is grim. Ex vivo expanded tumor-associated antigen (TAA)-reactive T-cells from patients with glioma may represent a viable source for anticancer-directed cellular therapies. Immunohistochemistry was used to test the survivin (n = 40 samples) and NY-ESO-1 (n = 38 samples) protein expression in tumor speci...
Rolf, Nina Smolen, Kinga K Kariminia, Amina Velenosi, Adam Fidanza, Mario Strahlendorf, Caron Seif, Alix E Reid, Gregor S D
Published in
Cancer immunology, immunotherapy : CII
Several retrospective studies in children with B cell precursor (BCP) acute lymphoblastic leukemia (ALL) provided clinical evidence that higher absolute lymphocyte counts (ALC) early into treatment significantly correlated with improved relapse-free and overall survival. It still remains unknown, however, whether the predictive role of higher ALCs ...
